Sharon X. Wen

Array ( [id] => 20227201 [patent_doc_number] => 12415844 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => BCMA specific VCAR compositions and methods for use [patent_app_type] => utility [patent_app_number] => 16/772262 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 28 [patent_no_of_words] => 126067 [patent_no_of_claims] => 79 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19425110 [patent_doc_number] => 12084513 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => Anti-C1S antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 16/763134 [patent_app_country] => US [patent_app_date] => 2018-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 47528 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14609597 [patent_doc_number] => 10357476 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-07-23 [patent_title] => Method for treating coronary artery disease [patent_app_type] => utility [patent_app_number] => 16/186495 [patent_app_country] => US [patent_app_date] => 2018-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4533 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16186495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720380 [patent_doc_number] => 20210087527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => ESTABLISHMENT AND APPLICATION OF HUMAN IMMORTALIZED B LYMPHOCYTE CELL LINE GROUP [patent_app_type] => utility [patent_app_number] => 16/771921 [patent_app_country] => US [patent_app_date] => 2018-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6251 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18071453 [patent_doc_number] => 11530276 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress [patent_app_type] => utility [patent_app_number] => 16/758881 [patent_app_country] => US [patent_app_date] => 2018-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 27398 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17556101 [patent_doc_number] => 11312777 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Human monoclonal antibodies that bind CXCR4 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/159306 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 26 [patent_no_of_words] => 37811 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 406 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16159306 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826683 [patent_doc_number] => 20190016826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => ANTI-HtrA1 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/143098 [patent_app_country] => US [patent_app_date] => 2018-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30353 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -81 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16143098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267309 [patent_doc_number] => 20200268796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => Compositions and Methods for Treating Heart Disease via Redirected T Cell Immunotherapies [patent_app_type] => utility [patent_app_number] => 16/651144 [patent_app_country] => US [patent_app_date] => 2018-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16651144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339326 [patent_doc_number] => 12049504 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Anti-hla-A2 antibodies and methods of using the same [patent_app_type] => utility [patent_app_number] => 16/648967 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 13 [patent_no_of_words] => 82564 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19121067 [patent_doc_number] => 11965038 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Pharmaceutical composition comprising antibody binding specifically to lysyl-tRNA synthetase N-terminus as effective ingredient for preventing or treating immune cell migration-related disease [patent_app_type] => utility [patent_app_number] => 16/646240 [patent_app_country] => US [patent_app_date] => 2018-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 27 [patent_no_of_words] => 24270 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 504 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283802 [patent_doc_number] => 20200277404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => COMPOSITIONS AND METHODS FOR REGULATION OF IMMUNE CELL ACTIVATION AND PROLIFERATION [patent_app_type] => utility [patent_app_number] => 16/645597 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253520 [patent_doc_number] => 20200262894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => STREP-TAG SPECIFIC BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/645428 [patent_app_country] => US [patent_app_date] => 2018-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24997 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618827 [patent_doc_number] => 20180360965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/121287 [patent_app_country] => US [patent_app_date] => 2018-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16121287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13736519 [patent_doc_number] => 20180372727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => METHODS AND KITS FOR PREDICTING THE RISK OF RELAPSE IN PATIENTS SUFFERING FROM IDIOPATHIC NEPHROTIC SYNDROME [patent_app_type] => utility [patent_app_number] => 16/119130 [patent_app_country] => US [patent_app_date] => 2018-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16119130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452624 [patent_doc_number] => 20200362050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => CD38 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/638205 [patent_app_country] => US [patent_app_date] => 2018-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13563885 [patent_doc_number] => 20180333490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) [patent_app_type] => utility [patent_app_number] => 16/053448 [patent_app_country] => US [patent_app_date] => 2018-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16053448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20415089 [patent_doc_number] => 12498367 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/632265 [patent_app_country] => US [patent_app_date] => 2018-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 23 [patent_no_of_words] => 37138 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 366 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16632265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13490259 [patent_doc_number] => 20180296672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => Methods for Treating Patients with Hypercholesterolemia that is not Adequately Controlled by Moderate-Dose Statin Therapy [patent_app_type] => utility [patent_app_number] => 16/022255 [patent_app_country] => US [patent_app_date] => 2018-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16022255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13661299 [patent_doc_number] => 10160801 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-25 [patent_title] => Nucleic acids encoding chimeric and humanized anti-histone antibodies [patent_app_type] => utility [patent_app_number] => 16/020276 [patent_app_country] => US [patent_app_date] => 2018-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 33600 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16020276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16832140 [patent_doc_number] => 11008381 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Antibodies to oxidized phospholipids [patent_app_type] => utility [patent_app_number] => 15/991662 [patent_app_country] => US [patent_app_date] => 2018-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 30 [patent_no_of_words] => 21366 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15991662 [rel_patent_id] =>[rel_patent_doc_number] =>)